Free Float 57,67 %
Shares Float 47,59 M
Shares Outstanding 82,53 M
BIVICTRIX THER.PLC LS-,01
Share · GB00BNXH3K91 · A3CWZM (XLON)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of BIVICTRIX THER.PLC LS-,01
No Price
Share Float & Liquidity
Company Profile for BIVICTRIX THER.PLC LS-,01 Share
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia. The company was formerly known as BiVictriX Plc and changed its name to BiVictriX Therapeutics Plc in August 2021. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.
Company Data
Name BIVICTRIX THER.PLC LS-,01
Company BiVictriX Therapeutics Plc
Website
https://www.bivictrix.com
Primary Exchange 
Frankfurt
Frankfurt
WKN A3CWZM
ISIN GB00BNXH3K91
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Tiffany Jane Thorn
Country United Kingdom
Currency EUR
Employees 0,0 T
Address Bio Hub, SK10 4TG Macclesfield
IPO Date 2021-08-11
Ticker Symbols
| Name | Symbol |
|---|---|
| Frankfurt | 4DE.F |
| London | BVX.L |
More Shares
Investors who hold BIVICTRIX THER.PLC LS-,01 also have the following shares in their portfolio:
